{"id":"naftifine","rwe":[{"pmid":"41743397","year":"2026","title":"Dupilumab for Atopic Dermatitis-Associated Nail Dystrophy: A Case Report.","finding":"","journal":"International medical case reports journal","studyType":"Clinical Study"},{"pmid":"41532771","year":"2026","title":"Protective mechanism of action of the antifungal drug naftifine against Mycobacterium abscessus infection.","finding":"","journal":"Antimicrobial agents and chemotherapy","studyType":"Clinical Study"},{"pmid":"40861206","year":"2025","title":"A case report of rapid diagnosis of Sporothrix globosa infection using MetaCAP.","finding":"","journal":"Frontiers in medicine","studyType":"Clinical Study"},{"pmid":"40374585","year":"2025","title":"Adsorption Configuration and H* Flux Modulation Enable Electrocatalytic Semihydrogenation of Alkynes with Group Tolerance in a Palladium Membrane Reactor.","finding":"","journal":"Journal of the American Chemical Society","studyType":"Clinical Study"},{"pmid":"40053133","year":"2025","title":"A comprehensive evaluation of Naftifine's efficacy and safety in treating dermatophyte infections; systematic review and meta-analysis.","finding":"","journal":"Archives of dermatological research","studyType":"Clinical Study"}],"_fda":{"id":"43150f38-df38-5e12-e063-6294a90a1128","set_id":"6645994a-ecb3-277b-e053-2a91aa0a81e5","openfda":{"unii":["25UR9N9041"],"route":["TOPICAL"],"rxcui":["1433734","1433736"],"spl_id":["43150f38-df38-5e12-e063-6294a90a1128"],"brand_name":["Naftin"],"spl_set_id":["6645994a-ecb3-277b-e053-2a91aa0a81e5"],"package_ndc":["54766-772-60","54766-772-45"],"product_ndc":["54766-772"],"generic_name":["NAFTIFINE HYDROCHLORIDE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["NAFTIFINE HYDROCHLORIDE"],"manufacturer_name":["Sebela Pharmaceuticals Inc."],"application_number":["NDA204286"],"is_original_packager":[true]},"version":"7","pregnancy":["8.1 Pregnancy Risk Summary There are no available data on NAFTIN® Gel use in pregnant women to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal reproduction studies, no adverse effects on embryofetal development were seen at oral doses administered during the period of organogenesis up to 37 times the maximum recommended human dose (MRHD) in pregnant rats or subcutaneous doses administered during the period of organogenesis up to 4 times the MRHD in pregnant rats or 7 times the MRHD in pregnant rabbits ( see Data ). All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data Systemic embryofetal development studies were conducted in rats and rabbits. For the comparison of animal to human doses, the MRHD is set at 4 g 2% gel per day (1.33 mg/kg/day for a 60 kg individual). Oral doses of 30, 100, and 300 mg/kg/day naftifine hydrochloride were administered during the period of organogenesis to pregnant female rats. No treatment-related effects on embryofetal toxicity were noted at doses up to 300 mg/kg/day (37 times the MRHD based on mg/m 2 comparison). Subcutaneous doses of 10 and 30 mg/kg/day naftifine hydrochloride were administered during the period of organogenesis to pregnant female rats. No treatment-related effects on embryofetal toxicity were noted at 30 mg/kg/day (4 times the MRHD based on mg/m 2 comparison). Subcutaneous doses of 3, 10, and 30 mg/kg/day naftifine hydrochloride were administered during the period of organogenesis to pregnant female rabbits. No treatment-related effects on embryofetal toxicity were noted at 30 mg/kg/day (7 times the MRHD based on mg/m 2 comparison). A peri-and post-natal development study was conducted in rats. Oral doses of 30, 100, and 300 mg/kg/day naftifine hydrochloride were administered to female rats from gestational day 14 to lactation day 21. Reduced body weight gain of females during gestation and of the offspring during lactation was noted at 300 mg/kg/day (37 times the MRHD based on mg/m 2 comparison). No developmental toxicity was noted at 100 mg/kg/day (12 times the MRHD based on mg/m 2 comparison)."],"description":["11 DESCRIPTION NAFTIN ® Gel is a clear to yellow gel for topical use only. Each gram of NAFTIN ® Gel contains 20 mg of naftifine hydrochloride, a synthetic allylamine antifungal compound. Chemically, naftifine HCl is (E)-N-Cinnamyl-N-methyl-1-napthalenemethylamine hydrochloride. The molecular formula is C 21 H 21 N∙HCl with a molecular weight of 323.86. The structural formula of naftifine hydrochloride is : NAFTIN ® Gel contains the following inactive ingredients: alcohol, benzyl alcohol, edetate disodium, hydroxyethyl cellulose, purified water, propylene glycol, polysorbate 20 and trolamine. Chemical Structure"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING How Supplied NAFTIN ® Gel is a colorless to yellow gel supplied in collapsible tubes in the following size: 45g – NDC 54766-772-45 60g – NDC 54766-772-60 Storage Store NAFTIN ® Gel at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]."],"microbiology":["12.4 Microbiology Mechanism of Action Naftifine is an antifungal that belongs to the allylamine class. Although the exact mechanism of action against fungi is not known, naftifine hydrochloride appears to interfere with sterol biosynthesis by inhibiting the enzyme squalene 2, 3-epoxidase. The inhibition of enzyme activity by this allylamine results in decreased amounts of sterols, especially ergosterol, and a corresponding accumulation of squalene in the cells. Mechanism of Resistance To date, a mechanism of resistance to naftifine has not been identified. Naftifine has been shown to be active against most isolates of the following fungi, both in vitro and in clinical infections, as described in the INDICATIONS AND USAGE section: Trichophyton rubrum Trichophyton mentagrophytes Epidermophyton floccosum"],"geriatric_use":["8.5 Geriatric Use During clinical trials, 99 subjects (9%) aged 65 years and over were exposed to NAFTIN ® Gel. Safety and effectiveness were similar to those reported by younger subjects."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of NAFTIN® Gel have been established in the age group 12 to 18 years of age with interdigital tinea pedis. Use of NAFTIN® Gel in this age group is supported by evidence from adequate and well controlled trials in adults with additional safety and PK data from an open label trial, conducted in 22 adolescents ≥12 years of age who were exposed to NAFTIN® Gel at a dose of approximately 4 g/day [see Clinical Pharmacology (12.3) ] . Safety and effectiveness in pediatric patients <12 years of age have not been established."],"effective_time":"20251108","clinical_studies":["14 CLINICAL STUDIES NAFTIN ® ​​ Gel has been evaluated for efficacy in two randomized, double-blind, vehicle-controlled, multicenter trials that included 1175 subjects with symptomatic and dermatophyte culture-positive interdigital tinea pedis. Subjects were randomized to receive NAFTIN ® Gel or vehicle. Subjects applied naftifine hydrochloride gel 2% or vehicle to the affected area of the foot once daily for 2 weeks. Signs and symptoms of interdigital tinea pedis (presence or absence of erythema, pruritus, and scaling) were assessed and potassium hydroxide (KOH) examination and dermatophyte culture were performed 6 weeks after the first treatment. The mean age of the study population was 45 years; 77% were male; and 60% were Caucasian, 35% were Black or African American, and 26% were Hispanic or Latino. At baseline, subjects were confirmed to have signs and symptoms of interdigital tinea pedis, positive KOH exam, and confirmed dermatophyte culture. The primary efficacy endpoint was the proportion of subjects with a complete cure at 6 weeks after the start of treatment (4 weeks after the last treatment). Complete cure was defined as both a clinical cure (absence of erythema, pruritus, and scaling) and mycological cure (negative KOH and dermatophyte culture). The efficacy results at week 6, four weeks following the end of treatment, are presented in Table 1 below. Table 1 Interdigital Tinea Pedis: Number (%) of Subjects with Complete Cure, Effective Treatment, and Mycological Cure at Week 6 Following Treatment with NAFTIN ® Gel (Full Analysis Set, Missing Values Treated as Treatment Failure) Trial 1 Trial 2 Endpoint NAFTIN ® Gel, 2% N=382 n (%) Vehicle N=179 n (%) NAFTIN ® Gel, 2% N=400 n (%) Vehicle N=213 n (%) Complete Cure Complete cure is a composite endpoint of both mycological cure and clinical cure. Clinical cure is defined as the absence of erythema, pruritus, and scaling (grade of 0). 64 (17%) 3 (2%) 104 (26%) 7 (3%) Treatment Effectiveness Effective treatment is a negative KOH preparation and negative dermatophyte culture, erythema, scaling, and pruritus grades of 0 or 1 (absent or nearly absent). 207 (54%) 11 (6%) 203 (51%) 15 (7%) Mycological Cure Mycological cure is defined as negative KOH and dermatophyte culture. 250 (65%) 25 (14%) 235 (59%) 22 (10%)"],"pharmacodynamics":["12.2 Pharmacodynamics The pharmacodynamics of NAFTIN ® Gel have not been established ."],"pharmacokinetics":["12.3 Pharmacokinetics In vitro and in vivo bioavailability studies have demonstrated that naftifine penetrates the stratum corneum in sufficient concentration to inhibit the growth of dermatophytes. Pharmacokinetic analysis of plasma samples from 32 subjects with tinea pedis treated with a mean dose of 3.9 grams NAFTIN ® Gel applied once daily to both feet for 14 days showed increased exposure over the treatment period, with a geometric mean (CV%) AUC 0-24 (area under plasma concentration-versus-time curve from time 0 to 24 hours) of 10.5 (118) ng∙hr/mL on Day 1 and an AUC 0-24 of 70 (59) ng∙hr/mL on Day 14. The accumulation ratio based on AUC was approximately 6. Maximum concentration (C max ) also increased over the treatment period; geometric mean (CV%) C max after a single dose was 0.9 (92) ng/mL on Day 1; C max on Day 14 was 3.7 (64) ng/mL. Median T max was 20.0 hours (range: 8, 20 hours) after a single application on Day 1 and 8.0 hours (range: 0, 24 hours) on Day 14. Trough plasma concentrations increased during the trial period and reached steady state after 11 days. In the same pharmacokinetic trial the fraction of dose excreted in urine during the treatment period was less than or equal to 0.01% of the applied dose. In a second trial, the pharmacokinetics of NAFTIN ® Gel was evaluated in 22 pediatric subjects 12-17 years of age with tinea pedis. Subjects were treated with a mean dose of 4.1 grams NAFTIN ® Gel applied to the affected area once daily for 14 days. The results showed that the systemic exposure increased over the treatment period. Geometric mean (CV%) AUC0-24 was 15.9 (212) ng∙hr/mL on Day 1 and 60.0 (131) ng∙hr/mL on Day 14. Geometric mean (CV%) Cmax after a single dose was 1.40 (154) ng/mL on Day 1 and 3.81 (154) ng/mL on Day 14. The fraction of dose excreted in urine during the treatment period was less than or equal to 0.003% of the applied dose."],"adverse_reactions":["6 ADVERSE REACTIONS The most common adverse reactions are application site reactions (2%). ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Sebela Pharmaceuticals Inc. at 1-888-271-4621 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. In two randomized, vehicle-controlled trials, 1143 subjects were treated with NAFTIN ® Gel versus 571 subjects treated with the vehicle. The trial subjects were 12 to 92 years old, were primarily male (76%), and were 59% Caucasian, 38% Black or African American, and 23% Hispanic or Latino. Subjects received doses once daily, topically, for 2 weeks to cover the affected skin areas plus a ½-inch margin of surrounding healthy skin. The most common adverse reactions were application site reactions which occurred at the rate of 2% in NAFTIN Gel arm versus 1% in vehicle arm. Most adverse reactions were mild in severity. In an open-label pediatric pharmacokinetics and safety trial 22 pediatric subjects 12-17 years of age with interdigital tinea pedis received NAFTIN ® Gel. The incidence of adverse reactions in the pediatric population was similar to that observed in adult population. Cumulative irritancy testing revealed the potential for NAFTIN ® Gel to cause irritation. There was no evidence that NAFTIN ® Gel causes contact sensitization, phototoxicity, or photoallergenicity in healthy skin. 6.2 Postmarketing Experience Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following adverse reactions have been identified during post-approval use of naftifine hydrochloride: blisters, burning sensation, crusting, dryness, erythema/redness, inflammation, irritation, maceration, pain, pruritus [mild]/itching, rash and swelling."],"contraindications":["4 CONTRAINDICATIONS None. None. ( 4 )"],"mechanism_of_action":["12.1 Mechanism of Action NAFTIN ® Gel is a topical antifungal drug [see Clinical Pharmacology (12.4) ] ."],"teratogenic_effects":["Risk Summary There are no available data on NAFTIN® Gel use in pregnant women to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal reproduction studies, no adverse effects on embryofetal development were seen at oral doses administered during the period of organogenesis up to 37 times the maximum recommended human dose (MRHD) in pregnant rats or subcutaneous doses administered during the period of organogenesis up to 4 times the MRHD in pregnant rats or 7 times the MRHD in pregnant rabbits ( see Data ). All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data Systemic embryofetal development studies were conducted in rats and rabbits. For the comparison of animal to human doses, the MRHD is set at 4 g 2% gel per day (1.33 mg/kg/day for a 60 kg individual). Oral doses of 30, 100, and 300 mg/kg/day naftifine hydrochloride were administered during the period of organogenesis to pregnant female rats. No treatment-related effects on embryofetal toxicity were noted at doses up to 300 mg/kg/day (37 times the MRHD based on mg/m 2 comparison). Subcutaneous doses of 10 and 30 mg/kg/day naftifine hydrochloride were administered during the period of organogenesis to pregnant female rats. No treatment-related effects on embryofetal toxicity were noted at 30 mg/kg/day (4 times the MRHD based on mg/m 2 comparison). Subcutaneous doses of 3, 10, and 30 mg/kg/day naftifine hydrochloride were administered during the period of organogenesis to pregnant female rabbits. No treatment-related effects on embryofetal toxicity were noted at 30 mg/kg/day (7 times the MRHD based on mg/m 2 comparison). A peri-and post-natal development study was conducted in rats. Oral doses of 30, 100, and 300 mg/kg/day naftifine hydrochloride were administered to female rats from gestational day 14 to lactation day 21. Reduced body weight gain of females during gestation and of the offspring during lactation was noted at 300 mg/kg/day (37 times the MRHD based on mg/m 2 comparison). No developmental toxicity was noted at 100 mg/kg/day (12 times the MRHD based on mg/m 2 comparison)."],"storage_and_handling":["Storage Store NAFTIN ® Gel at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action NAFTIN ® Gel is a topical antifungal drug [see Clinical Pharmacology (12.4) ] . 12.2 Pharmacodynamics The pharmacodynamics of NAFTIN ® Gel have not been established . 12.3 Pharmacokinetics In vitro and in vivo bioavailability studies have demonstrated that naftifine penetrates the stratum corneum in sufficient concentration to inhibit the growth of dermatophytes. Pharmacokinetic analysis of plasma samples from 32 subjects with tinea pedis treated with a mean dose of 3.9 grams NAFTIN ® Gel applied once daily to both feet for 14 days showed increased exposure over the treatment period, with a geometric mean (CV%) AUC 0-24 (area under plasma concentration-versus-time curve from time 0 to 24 hours) of 10.5 (118) ng∙hr/mL on Day 1 and an AUC 0-24 of 70 (59) ng∙hr/mL on Day 14. The accumulation ratio based on AUC was approximately 6. Maximum concentration (C max ) also increased over the treatment period; geometric mean (CV%) C max after a single dose was 0.9 (92) ng/mL on Day 1; C max on Day 14 was 3.7 (64) ng/mL. Median T max was 20.0 hours (range: 8, 20 hours) after a single application on Day 1 and 8.0 hours (range: 0, 24 hours) on Day 14. Trough plasma concentrations increased during the trial period and reached steady state after 11 days. In the same pharmacokinetic trial the fraction of dose excreted in urine during the treatment period was less than or equal to 0.01% of the applied dose. In a second trial, the pharmacokinetics of NAFTIN ® Gel was evaluated in 22 pediatric subjects 12-17 years of age with tinea pedis. Subjects were treated with a mean dose of 4.1 grams NAFTIN ® Gel applied to the affected area once daily for 14 days. The results showed that the systemic exposure increased over the treatment period. Geometric mean (CV%) AUC0-24 was 15.9 (212) ng∙hr/mL on Day 1 and 60.0 (131) ng∙hr/mL on Day 14. Geometric mean (CV%) Cmax after a single dose was 1.40 (154) ng/mL on Day 1 and 3.81 (154) ng/mL on Day 14. The fraction of dose excreted in urine during the treatment period was less than or equal to 0.003% of the applied dose. 12.4 Microbiology Mechanism of Action Naftifine is an antifungal that belongs to the allylamine class. Although the exact mechanism of action against fungi is not known, naftifine hydrochloride appears to interfere with sterol biosynthesis by inhibiting the enzyme squalene 2, 3-epoxidase. The inhibition of enzyme activity by this allylamine results in decreased amounts of sterols, especially ergosterol, and a corresponding accumulation of squalene in the cells. Mechanism of Resistance To date, a mechanism of resistance to naftifine has not been identified. Naftifine has been shown to be active against most isolates of the following fungi, both in vitro and in clinical infections, as described in the INDICATIONS AND USAGE section: Trichophyton rubrum Trichophyton mentagrophytes Epidermophyton floccosum"],"indications_and_usage":["1 INDICATIONS AND USAGE NAFTIN ® Gel is an allylamine antifungal indicated for the treatment of interdigital tinea pedis caused by the organisms Trichophyton rubrum , Trichophyton mentagrophytes , and Epidermophyton floccosum . NAFTIN ® Gel is an allylamine antifungal indicated for the treatment of interdigital tinea pedis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum . ( 1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS If redness or irritation develops with the use of NAFTIN ® Gel treatment should be discontinued. ( 5.1 ) 5.1 Local Adverse Reactions If irritation or sensitivity develops with the use of NAFTIN ® Gel, treatment should be discontinued."],"clinical_studies_table":["<table width=\"100%\" ID=\"table1\"><caption>Table 1 Interdigital Tinea Pedis: Number (%) of Subjects with Complete Cure, Effective Treatment, and Mycological Cure at Week 6 Following Treatment with NAFTIN <sup>&#xAE;</sup>Gel (Full Analysis Set, Missing Values Treated as Treatment Failure) </caption><col align=\"left\" valign=\"top\" width=\"30%\"/><col align=\"center\" valign=\"top\" width=\"17%\"/><col align=\"center\" valign=\"top\" width=\"18%\"/><col align=\"center\" valign=\"top\" width=\"17%\"/><col align=\"center\" valign=\"top\" width=\"18%\"/><thead><tr styleCode=\"Botrule First\"><th align=\"left\" styleCode=\"Lrule Rrule\"/><th align=\"center\" colspan=\"2\" styleCode=\"Rrule\">Trial 1</th><th align=\"center\" colspan=\"2\" styleCode=\"Rrule\">Trial 2</th></tr><tr><th align=\"center\" styleCode=\"Lrule Rrule\" valign=\"bottom\">Endpoint</th><th align=\"center\" styleCode=\"Rrule\">NAFTIN <sup>&#xAE;</sup>Gel, 2%      N=382      n (%) </th><th align=\"center\" styleCode=\"Rrule\">Vehicle      N=179      n (%) </th><th align=\"center\" styleCode=\"Rrule\">NAFTIN <sup>&#xAE;</sup>Gel, 2%      N=400      n (%) </th><th align=\"center\" styleCode=\"Rrule\">Vehicle      N=213      n (%) </th></tr></thead><tbody><tr styleCode=\"Botrule First\"><td align=\"left\" styleCode=\"Lrule Rrule\">Complete Cure <footnote ID=\"K988\">Complete cure is a composite endpoint of both mycological cure and clinical cure. Clinical cure is defined as the absence of erythema, pruritus, and scaling (grade of 0).</footnote></td><td align=\"center\" styleCode=\"Rrule\">64 (17%)</td><td align=\"center\" styleCode=\"Rrule\">3 (2%)</td><td align=\"center\" styleCode=\"Rrule\">104 (26%)</td><td align=\"center\" styleCode=\"Rrule\">7 (3%)</td></tr><tr styleCode=\"Botrule\"><td align=\"left\" styleCode=\"Lrule Rrule\">Treatment Effectiveness <footnote ID=\"K1007\">Effective treatment is a negative KOH preparation and negative dermatophyte culture, erythema, scaling, and pruritus grades of 0 or 1 (absent or nearly absent).</footnote></td><td align=\"center\" styleCode=\"Rrule\">207 (54%)</td><td align=\"center\" styleCode=\"Rrule\">11 (6%)</td><td align=\"center\" styleCode=\"Rrule\">203 (51%)</td><td align=\"center\" styleCode=\"Rrule\">15 (7%)</td></tr><tr><td align=\"left\" styleCode=\"Lrule Rrule\">Mycological Cure <footnote ID=\"K1025\">Mycological cure is defined as negative KOH and dermatophyte culture.</footnote></td><td align=\"center\" styleCode=\"Rrule\">250 (65%)</td><td align=\"center\" styleCode=\"Rrule\">25 (14%)</td><td align=\"center\" styleCode=\"Rrule\">235 (59%)</td><td align=\"center\" styleCode=\"Rrule\">22 (10%)</td></tr></tbody></table>"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility In a 2-year dermal carcinogenicity study, naftifine hydrochloride cream was administered to Sprague-Dawley rats at topical doses of 1%, 2% and 3% (10, 20, and 30 mg/kg/day naftifine hydrochloride). No drug-related tumors were noted in this study up to the highest dose evaluated in this study of 30 mg/kg/day (36 times the MRHD based on AUC comparison). Naftifine hydrochloride revealed no evidence of mutagenic or clastogenic potential based on the results of two in vitro genotoxicity tests (Ames assay and Chinese hamster ovary cell chromosome aberration assay) and one in vivo genotoxicity test (mouse bone marrow micronucleus assay). Oral administration of naftifine hydrochloride to rats, throughout mating, gestation, parturition, and lactation, demonstrated no effects on growth, fertility, or reproduction, at doses up to 100 mg/kg/day (12 times the MRHD based on mg/m 2 ​ comparison)."],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Inform patients that NAFTIN ® Gel is for topical use only. NAFTIN ® Gel is not intended for ophthalmic, oral, or intravaginal use. Patients should be directed to contact their physician if irritation develops with the use of NAFTIN ® Gel."],"spl_unclassified_section":["Distributed by Sebela Pharmaceuticals Inc. 645 Hembree Parkway, Suite I, Roswell, GA 30076 www.sebelapharma.com Toll Free 1-844-732-3521 ©​2020 Sebela Pharmaceuticals Inc. All rights reserved."],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Apply a thin layer of NAFTIN ® Gel once daily to the affected areas plus an approximate ½ inch margin of healthy surrounding skin for 2 weeks. For topical use only. NAFTIN ® Gel is not for ophthalmic, oral, or intravaginal use. Apply a thin layer of NAFTIN ® Gel once daily to the affected areas plus an approximate ½ inch margin of healthy surrounding skin for 2 weeks. ( 2 ) For topical use only. NAFTIN ® Gel is not for ophthalmic, oral, or intravaginal use. ( 2 )"],"spl_product_data_elements":["Naftin Naftifine Hydrochloride WATER PROPYLENE GLYCOL POLYSORBATE 20 ALCOHOL HYDROXYETHYL CELLULOSE (2000 MPA.S AT 1%) BENZYL ALCOHOL TROLAMINE EDETATE DISODIUM NAFTIFINE HYDROCHLORIDE NAFTIFINE"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Gel, 2%. Each gram contains 20 mg of naftifine hydrochloride in a colorless to yellow gel. Gel, 2%. ( 3 )"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary There are no available data on NAFTIN® Gel use in pregnant women to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal reproduction studies, no adverse effects on embryofetal development were seen at oral doses administered during the period of organogenesis up to 37 times the maximum recommended human dose (MRHD) in pregnant rats or subcutaneous doses administered during the period of organogenesis up to 4 times the MRHD in pregnant rats or 7 times the MRHD in pregnant rabbits ( see Data ). All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data Systemic embryofetal development studies were conducted in rats and rabbits. For the comparison of animal to human doses, the MRHD is set at 4 g 2% gel per day (1.33 mg/kg/day for a 60 kg individual). Oral doses of 30, 100, and 300 mg/kg/day naftifine hydrochloride were administered during the period of organogenesis to pregnant female rats. No treatment-related effects on embryofetal toxicity were noted at doses up to 300 mg/kg/day (37 times the MRHD based on mg/m 2 comparison). Subcutaneous doses of 10 and 30 mg/kg/day naftifine hydrochloride were administered during the period of organogenesis to pregnant female rats. No treatment-related effects on embryofetal toxicity were noted at 30 mg/kg/day (4 times the MRHD based on mg/m 2 comparison). Subcutaneous doses of 3, 10, and 30 mg/kg/day naftifine hydrochloride were administered during the period of organogenesis to pregnant female rabbits. No treatment-related effects on embryofetal toxicity were noted at 30 mg/kg/day (7 times the MRHD based on mg/m 2 comparison). A peri-and post-natal development study was conducted in rats. Oral doses of 30, 100, and 300 mg/kg/day naftifine hydrochloride were administered to female rats from gestational day 14 to lactation day 21. Reduced body weight gain of females during gestation and of the offspring during lactation was noted at 300 mg/kg/day (37 times the MRHD based on mg/m 2 comparison). No developmental toxicity was noted at 100 mg/kg/day (12 times the MRHD based on mg/m 2 comparison). 8.2 Lactation Risk Summary There is no information available on the presence of naftifine hydrochloride in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production after topical application of NAFTIN Gel to women who are breastfeeding. It is not known whether naftifine hydrochloride is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when naftifine hydrochloride is administered to a nursing woman. The lack of clinical data during lactation precludes a clear determination of the risk NAFTIN Gel to an infant during lactation. Therefore, the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for NAFTIN gel and any potential adverse effects on the breastfed infant from NAFTIN gel or from the underlying maternal condition. 8.4 Pediatric Use The safety and effectiveness of NAFTIN® Gel have been established in the age group 12 to 18 years of age with interdigital tinea pedis. Use of NAFTIN® Gel in this age group is supported by evidence from adequate and well controlled trials in adults with additional safety and PK data from an open label trial, conducted in 22 adolescents ≥12 years of age who were exposed to NAFTIN® Gel at a dose of approximately 4 g/day [see Clinical Pharmacology (12.3) ] . Safety and effectiveness in pediatric patients <12 years of age have not been established. 8.5 Geriatric Use During clinical trials, 99 subjects (9%) aged 65 years and over were exposed to NAFTIN ® Gel. Safety and effectiveness were similar to those reported by younger subjects."],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 45g Tube Carton NDC 54766-772-45 NAFTIN ® (Naftifine Hydrochloride) Gel, 2% Sebela Pharmaceuticals Inc. For Topical Use Only Not for Ophthalmic, Oral or Intravaginal Use 45g Rx Only 45g Carton","PRINCIPAL DISPLAY PANEL - 60 g Tube Carton NDC 54766-772-60 NAFTIN ® (Naftifine Hydrochloride) Gel, 2 % Sebela Pharmaceuticals Inc. For Topical Use Only Not for Ophthalmic, Oral or Intravaginal Use 60g Rx Only 60g Carton"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility In a 2-year dermal carcinogenicity study, naftifine hydrochloride cream was administered to Sprague-Dawley rats at topical doses of 1%, 2% and 3% (10, 20, and 30 mg/kg/day naftifine hydrochloride). No drug-related tumors were noted in this study up to the highest dose evaluated in this study of 30 mg/kg/day (36 times the MRHD based on AUC comparison). Naftifine hydrochloride revealed no evidence of mutagenic or clastogenic potential based on the results of two in vitro genotoxicity tests (Ames assay and Chinese hamster ovary cell chromosome aberration assay) and one in vivo genotoxicity test (mouse bone marrow micronucleus assay). Oral administration of naftifine hydrochloride to rats, throughout mating, gestation, parturition, and lactation, demonstrated no effects on growth, fertility, or reproduction, at doses up to 100 mg/kg/day (12 times the MRHD based on mg/m 2 ​ comparison)."]},"tags":[{"label":"Allylamine Antifungal","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Sigma non-opioid intracellular receptor 1","category":"target"},{"label":"SIGMAR1","category":"gene"},{"label":"EBP","category":"gene"},{"label":"SQLE","category":"gene"},{"label":"D01AE22","category":"atc"},{"label":"Topical","category":"route"},{"label":"Cream","category":"form"},{"label":"Gel","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Tinea corporis","category":"indication"},{"label":"Tinea cruris","category":"indication"},{"label":"Tinea pedis","category":"indication"},{"label":"Legacy Pharma","category":"company"},{"label":"Approved 1980s","category":"decade"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Antifungal Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"llr":39.719,"date":"","count":12,"signal":"Skin exfoliation","source":"DrugCentral FAERS","actionTaken":"Reported 12 times (LLR=40)"}],"commonSideEffects":[{"effect":"application site reactions","drugRate":"2%","_validated":true,"placeboRate":"1%"}],"specialPopulations":{"Pregnancy":"There are no available data with naftifine hydrochloride cream in pregnant women to inform the drug-associated risk for major birth defects and miscarriage. In animal reproduction studies, no adverse effects on embryofetal development were seen at oral doses administered during the period of organogenesis up to 18 times the maximum recommended human dose (MRHD) in pregnant rats or subcutaneous doses administered during the period of organogenesis up to times the MRHD in pregnant rats or times the MRHD in pregnant rabbits. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Reproduction studies have been performed in rats and rabbits (via oral administration) at doses 150 times or more than the topical human dose and have revealed no evidence of impaired fertility or harm to the fetus due to naftifine. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.","Geriatric use":"During clinical trials, 99 subjects (9%) aged 65 years and over were exposed to naftifine hydrochloride gel. Safety and effectiveness were similar to those reported by younger subjects.","Paediatric use":"Safety and effectiveness in pediatric patients have not been established."}},"trials":[],"aliases":[],"company":"Legacy Pharma","patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$2.5430/GM","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$928","description":"NAFTIFINE HCL 2% CREAM","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=NAFTIFINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:50:33.515084+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Naftifine","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T02:50:40.778916+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T02:51:03.194892+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:50:39.389361+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NAFTIFINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:50:39.725261+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:50:32.377683+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:50:57.259688+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:50:32.377729+00:00"},"mechanism.oneSentence":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"12.1 Mechanism of Action NAFTIN ® Gel is a topical antifungal drug [see Clinical Pharmacology (12.4) ] .","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:50:45.321606+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL626/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:50:40.426487+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"6 ADVERSE REACTIONS The most common adverse reactions are application site reactions (2%). ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Sebela Pharmaceuticals Inc. at 1-888-271-4621 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not ref","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:50:49.109925+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA204286","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:50:32.377733+00:00"}},"allNames":"naftin","offLabel":[],"synonyms":["naftifine","naftifine hydrochloride","naftifungin","naftifine HCl","naftifin"],"timeline":[{"date":"1988-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from MERZ PHARMS to Legacy Pharma"},{"date":"1988-02-29","type":"positive","source":"DrugCentral","milestone":"FDA approval (Merz Pharms)"},{"date":"1990-06-18","type":"positive","source":"FDA Orange Book","milestone":"Naftin approved — 1%"},{"date":"2013-06-27","type":"positive","source":"FDA Orange Book","milestone":"Naftin approved — 2%"},{"date":"2017-04-10","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 2 manufacturers approved"}],"aiSummary":"Naftifine, marketed by Legacy Pharma, is an antifungal treatment primarily indicated for interdigital tinea pedis, with a key composition patent expiring in 2028. Its mechanism of action, which inhibits ergosterol synthesis in fungal cell membranes, provides a targeted approach to treating fungal infections. The primary risk is the competitive landscape, including off-patent drugs like selenium sulfide and ciclopirox, which are widely available as generics.","approvals":[{"date":"1988-02-29","orphan":false,"company":"MERZ PHARMS","regulator":"FDA"}],"brandName":"Naftin","ecosystem":[{"indication":"Tinea corporis","otherDrugs":[{"name":"benzocaine","slug":"benzocaine","company":""},{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone dipropionate","slug":"betamethasone-dipropionate","company":"Schering"},{"name":"butenafine","slug":"butenafine","company":"Mylan"}],"globalPrevalence":null},{"indication":"Tinea cruris","otherDrugs":[{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone dipropionate","slug":"betamethasone-dipropionate","company":"Schering"},{"name":"butenafine","slug":"butenafine","company":"Mylan"},{"name":"ciclopirox","slug":"ciclopirox","company":"Medimetriks Pharms"}],"globalPrevalence":null},{"indication":"Tinea pedis","otherDrugs":[{"name":"benzocaine","slug":"benzocaine","company":""},{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone dipropionate","slug":"betamethasone-dipropionate","company":"Schering"},{"name":"butenafine","slug":"butenafine","company":"Mylan"}],"globalPrevalence":640000000}],"mechanism":{"target":"Sigma non-opioid intracellular receptor 1","novelty":"Follow-on","targets":[{"gene":"SIGMAR1","source":"DrugCentral","target":"Sigma non-opioid intracellular receptor 1","protein":"Sigma non-opioid intracellular receptor 1"},{"gene":"EBP","source":"DrugCentral","target":"3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase","protein":"3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase"},{"gene":"SQLE","source":"DrugCentral","target":"Squalene monooxygenase","protein":"Squalene monooxygenase"}],"modality":"Small Molecule","drugClass":"Allylamine Antifungal","explanation":"Naftifine hydrochloride gel is topical antifungal drug [see Clinical Pharmacology (12.4)].","oneSentence":"Naftin works by inhibiting the synthesis of ergosterol in fungal cell membranes.","technicalDetail":"Naftin exerts its antifungal effects by inhibiting squalene epoxidase, an enzyme essential for the biosynthesis of ergosterol, a critical component of fungal cell membranes.","_target_confidence":0.5},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Naftifine","title":"Naftifine","extract":"Naftifine hydrochloride is an allylamine antifungal drug for the topical treatment of tinea pedis, tinea cruris, and tinea corporis."},"commercial":{"launchDate":"1988","_launchSource":"DrugCentral (FDA 1988-02-29, MERZ PHARMS)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1872","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=NAFTIFINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NAFTIFINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Naftifine","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T14:36:36.540611","_validation":{"fieldsValidated":4,"lastValidatedAt":"2026-04-20T02:51:03.195687+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"undecylenic acid","drugSlug":"undecylenic-acid","fdaApproval":"","relationship":"same-class"},{"drugName":"chlorphenesin carbamate","drugSlug":"chlorphenesin-carbamate","fdaApproval":"1965-06-14","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"haloprogin","drugSlug":"haloprogin","fdaApproval":"","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"selenium sulfide","drugSlug":"selenium-sulfide","fdaApproval":"1951-05-17","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ciclopirox","drugSlug":"ciclopirox","fdaApproval":"1982-12-30","genericCount":17,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"terbinafine","drugSlug":"terbinafine","fdaApproval":"1992-12-30","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"tolnaftate","drugSlug":"tolnaftate","fdaApproval":"","relationship":"same-class"},{"drugName":"flucytosine","drugSlug":"flucytosine","fdaApproval":"1971-11-26","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"butenafine","drugSlug":"butenafine","fdaApproval":"1996-10-18","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"tavaborole","drugSlug":"tavaborole","fdaApproval":"2014-07-07","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"naftifine","indications":{"approved":[{"id":"naftifine-interdigital-tinea-pedis","name":"Interdigital tinea pedis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with interdigital tinea pedis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with interdigital tinea pedis","diagnosticRequired":null,"brandNameForIndication":"Naftin"}],"offLabel":[{"name":"Pityriasis versicolor","source":"DrugCentral","drugName":"NAFTIFINE","evidenceCount":8,"evidenceLevel":"emerging"}],"pipeline":[]},"currentOwner":"Legacy Pharma","drugCategory":"mature","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"undecylenic-acid","brandName":"undecylenic acid","genericName":"undecylenic acid","approvalYear":"","relationship":"same-class"},{"drugId":"chlorphenesin-carbamate","brandName":"chlorphenesin carbamate","genericName":"chlorphenesin carbamate","approvalYear":"1965","relationship":"same-class"},{"drugId":"haloprogin","brandName":"haloprogin","genericName":"haloprogin","approvalYear":"","relationship":"same-class"},{"drugId":"selenium-sulfide","brandName":"selenium sulfide","genericName":"selenium sulfide","approvalYear":"1951","relationship":"same-class"},{"drugId":"ciclopirox","brandName":"ciclopirox","genericName":"ciclopirox","approvalYear":"1982","relationship":"same-class"},{"drugId":"terbinafine","brandName":"terbinafine","genericName":"terbinafine","approvalYear":"1992","relationship":"same-class"},{"drugId":"tolnaftate","brandName":"tolnaftate","genericName":"tolnaftate","approvalYear":"","relationship":"same-class"},{"drugId":"flucytosine","brandName":"flucytosine","genericName":"flucytosine","approvalYear":"1971","relationship":"same-class"},{"drugId":"butenafine","brandName":"butenafine","genericName":"butenafine","approvalYear":"1996","relationship":"same-class"},{"drugId":"tavaborole","brandName":"tavaborole","genericName":"tavaborole","approvalYear":"2014","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05363449","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis","status":"COMPLETED","sponsor":"Therapeutics, Inc.","startDate":"2022-02-17","conditions":["Tinea Cruris","Tinea Pedis"],"enrollment":42,"completionDate":"2023-11-14"},{"nctId":"NCT02335255","phase":"PHASE1","title":"Evaluate Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® Gel 2% in Tinea Pedis","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2014-06-27","conditions":["Tinea Pedis"],"enrollment":1519,"completionDate":"2018-05-15"},{"nctId":"NCT02633813","phase":"PHASE3","title":"BE Study of Naftifine HCL","status":"COMPLETED","sponsor":"Genzum Life Sciences","startDate":"2015-03","conditions":["Tinea Pedis"],"enrollment":693,"completionDate":"2015-12"},{"nctId":"NCT02132260","phase":"PHASE1","title":"Evaluate the Safety and Efficacy of Naftifine Hydrochloride Cream 2% and Naftin® Cream 2% in Patients With Tinea Pedis","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2013-08","conditions":["Tinea Pedis"],"enrollment":890,"completionDate":"2014-03"},{"nctId":"NCT02227290","phase":"PHASE4","title":"Pediatric Subjects With Tinea Corporis","status":"COMPLETED","sponsor":"Merz North America, Inc.","startDate":"2014-08","conditions":["Tinea Corporis"],"enrollment":230,"completionDate":"2015-12"},{"nctId":"NCT02466867","phase":"PHASE4","title":"An Open Label Pharmacokinetic Study of Naftin for Tinea Corporis","status":"COMPLETED","sponsor":"Merz North America, Inc.","startDate":"2014-01","conditions":["Tinea Corporis"],"enrollment":27,"completionDate":"2015-12"},{"nctId":"NCT02658292","phase":"PHASE2","title":"Safety and Efficacy of NAFT900 in Children With Tinea Capitis","status":"WITHDRAWN","sponsor":"Merz North America, Inc.","startDate":"","conditions":["Tinea Capitis"],"enrollment":0,"completionDate":""},{"nctId":"NCT01712360","phase":"PHASE4","title":"Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis","status":"COMPLETED","sponsor":"Merz North America, Inc.","startDate":"2012-10","conditions":["Tinea Pedis","Tinea Cruris"],"enrollment":56,"completionDate":"2013-11"},{"nctId":"NCT01885156","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Naftin 1% Cream in Adolescent Subjects With Tinea Cruris","status":"COMPLETED","sponsor":"Merz North America, Inc.","startDate":"2013-08","conditions":["Tinea Cruris","Jock Itch"],"enrollment":65,"completionDate":"2013-11"},{"nctId":"NCT01580891","phase":"PHASE1","title":"Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2012-05","conditions":["Tinea Pedis"],"enrollment":1053,"completionDate":"2013-07"},{"nctId":"NCT01290341","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis","status":"COMPLETED","sponsor":"Merz North America, Inc.","startDate":"2011-02","conditions":["Tinea Pedis"],"enrollment":860,"completionDate":"2011-12"},{"nctId":"NCT01289015","phase":"PHASE3","title":"Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis","status":"COMPLETED","sponsor":"Merz North America, Inc.","startDate":"2011-02","conditions":["Tinea Pedis"],"enrollment":855,"completionDate":"2012-01"},{"nctId":"NCT00750139","phase":"PHASE3","title":"Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis","status":"COMPLETED","sponsor":"Merz North America, Inc.","startDate":"2008-08","conditions":["Tinea Pedis","Athlete's Foot"],"enrollment":707,"completionDate":"2009-12"},{"nctId":"NCT00253305","phase":"PHASE2","title":"Topical Gel Anti-Fungal Agent for Tinea Unguium","status":"COMPLETED","sponsor":"MediQuest Therapeutics","startDate":"2005-09","conditions":["Onychomycosis"],"enrollment":75,"completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Topical","formulation":"Cream, Gel","formulations":[{"form":"CREAM","route":"TOPICAL","productName":"NAFTIFINE HYDROCHLORIDE"},{"form":"CREAM","route":"TOPICAL","productName":"Naftifine Hydrochloride"},{"form":"CREAM","route":"TOPICAL","productName":"Naftifine hydrochloride"},{"form":"CREAM","route":"TOPICAL","productName":"Naftin"},{"form":"GEL","route":"TOPICAL","productName":"NAFTIFINE HYDROCHLORIDE"},{"form":"GEL","route":"TOPICAL","productName":"Naftifine Hydrochloride"},{"form":"GEL","route":"TOPICAL","productName":"Naftin"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000171577","MMSL":"234377","NDDF":"002929","UNII":"4FB1TON47A","VUID":"4019850","CHEBI":"CHEBI:7451","VANDF":"4019526","INN_ID":"4588","RXNORM":"31476","UMLSCUI":"C0068367","chemblId":"CHEMBL626","ChEMBL_ID":"CHEMBL626","KEGG_DRUG":"D00883","DRUGBANK_ID":"DB00735","PUBCHEM_CID":"47641","SNOMEDCT_US":"13800009","SECONDARY_CAS_RN":"65473-14-5","MESH_SUPPLEMENTAL_RECORD_UI":"C029178"},"formularyStatus":[],"originalProduct":{"form":"CREAM","route":"TOPICAL","company":"Merz Pharmaceuticals, LLC","brandName":"Naftin","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1988-","companyName":"Merz Pharms","relationship":"Original Developer"},{"period":"present","companyName":"Legacy Pharma","relationship":"Current Owner"}],"publicationCount":206,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"D01AE22","allCodes":["D01AE22"]},"biosimilarFilings":[],"originalDeveloper":"Merz Pharms","recentPublications":[{"date":"2026","pmid":"41743397","title":"Dupilumab for Atopic Dermatitis-Associated Nail Dystrophy: A Case Report.","journal":"International medical case reports journal"},{"date":"2026 Feb 4","pmid":"41532771","title":"Protective mechanism of action of the antifungal drug naftifine against Mycobacterium abscessus infection.","journal":"Antimicrobial agents and chemotherapy"},{"date":"2025","pmid":"40861206","title":"A case report of rapid diagnosis of Sporothrix globosa infection using MetaCAP.","journal":"Frontiers in medicine"},{"date":"2025 May 28","pmid":"40374585","title":"Adsorption Configuration and H* Flux Modulation Enable Electrocatalytic Semihydrogenation of Alkynes with Group Tolerance in a Palladium Membrane Reactor.","journal":"Journal of the American Chemical Society"},{"date":"2025 Mar 7","pmid":"40053133","title":"A comprehensive evaluation of Naftifine's efficacy and safety in treating dermatophyte infections; systematic review and meta-analysis.","journal":"Archives of dermatological research"}],"companionDiagnostics":[],"genericManufacturers":3,"_genericFilersChecked":true,"genericManufacturerList":["Amneal","Sun Pharma Canada","Xiromed"],"status":"approved","companyName":"Legacy Pharma","companyId":"legacy-pharma","modality":"Small molecule","firstApprovalDate":"1988","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1988-02-29T00:00:00.000Z","mah":"MERZ PHARMS","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":4,"lastValidatedAt":"2026-04-20T02:51:03.195687+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}